Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients

A. Salmaggi, C. Milanese, M. Eoli, L. La Mantia, A. Nespolo, A. Dufour

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

15 patients with progressive Multiple Sclerosis (MS) were treated by an induction Cyclophosphamide (CFX) schedule followed by bimonthly boosters over one year. Of the 14 patients who completed the trial, only two displayed worsening of neurological status. Cerebrospinal fluid (CSF) total protein, IgG/Alb ratio and IgG index decreased at 6 months and were still low at the end of the treatment. Pretreatment percentages of PB CD8+ and CD4+CD45RA+ lymphocytes were lower in MS patients in comparison with healthy controls. However, no significant shifts occurred in percentage of PB CD4+, CD4+CD45RA+, CD4+CD45RA-, CD8+ lymphocytes of MS patients during immunosuppressive treatment. The lack of changes in the investigated immunological parameters contrasts with the good clinical response and the low rate of serious side effects during this treatment schedule.

Original languageEnglish
Pages (from-to)305-312
Number of pages8
JournalInternational Journal of Neuroscience
Volume76
Issue number3-4
DOIs
Publication statusPublished - 1994

Fingerprint

Immunologic Monitoring
Cyclophosphamide
Multiple Sclerosis
Appointments and Schedules
Immunoglobulin G
Lymphocytes
Cerebrospinal Fluid Proteins
Immunosuppressive Agents
Therapeutics

Keywords

  • Cerebrospinal fluid
  • Cyclophosphamide
  • Multiple Sclerosis
  • T-cell subsets

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients. / Salmaggi, A.; Milanese, C.; Eoli, M.; Mantia, L. La; Nespolo, A.; Dufour, A.

In: International Journal of Neuroscience, Vol. 76, No. 3-4, 1994, p. 305-312.

Research output: Contribution to journalArticle

Salmaggi, A. ; Milanese, C. ; Eoli, M. ; Mantia, L. La ; Nespolo, A. ; Dufour, A. / Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients. In: International Journal of Neuroscience. 1994 ; Vol. 76, No. 3-4. pp. 305-312.
@article{7c5772070cf4415e9833e351aa792764,
title = "Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients",
abstract = "15 patients with progressive Multiple Sclerosis (MS) were treated by an induction Cyclophosphamide (CFX) schedule followed by bimonthly boosters over one year. Of the 14 patients who completed the trial, only two displayed worsening of neurological status. Cerebrospinal fluid (CSF) total protein, IgG/Alb ratio and IgG index decreased at 6 months and were still low at the end of the treatment. Pretreatment percentages of PB CD8+ and CD4+CD45RA+ lymphocytes were lower in MS patients in comparison with healthy controls. However, no significant shifts occurred in percentage of PB CD4+, CD4+CD45RA+, CD4+CD45RA-, CD8+ lymphocytes of MS patients during immunosuppressive treatment. The lack of changes in the investigated immunological parameters contrasts with the good clinical response and the low rate of serious side effects during this treatment schedule.",
keywords = "Cerebrospinal fluid, Cyclophosphamide, Multiple Sclerosis, T-cell subsets",
author = "A. Salmaggi and C. Milanese and M. Eoli and Mantia, {L. La} and A. Nespolo and A. Dufour",
year = "1994",
doi = "10.3109/00207459408986012",
language = "English",
volume = "76",
pages = "305--312",
journal = "International Journal of Neuroscience",
issn = "0020-7454",
publisher = "Informa Healthcare",
number = "3-4",

}

TY - JOUR

T1 - Immunological monitoring and clinical evaluation in cyclophosphamide-treated progressive multiple sclerosis patients

AU - Salmaggi, A.

AU - Milanese, C.

AU - Eoli, M.

AU - Mantia, L. La

AU - Nespolo, A.

AU - Dufour, A.

PY - 1994

Y1 - 1994

N2 - 15 patients with progressive Multiple Sclerosis (MS) were treated by an induction Cyclophosphamide (CFX) schedule followed by bimonthly boosters over one year. Of the 14 patients who completed the trial, only two displayed worsening of neurological status. Cerebrospinal fluid (CSF) total protein, IgG/Alb ratio and IgG index decreased at 6 months and were still low at the end of the treatment. Pretreatment percentages of PB CD8+ and CD4+CD45RA+ lymphocytes were lower in MS patients in comparison with healthy controls. However, no significant shifts occurred in percentage of PB CD4+, CD4+CD45RA+, CD4+CD45RA-, CD8+ lymphocytes of MS patients during immunosuppressive treatment. The lack of changes in the investigated immunological parameters contrasts with the good clinical response and the low rate of serious side effects during this treatment schedule.

AB - 15 patients with progressive Multiple Sclerosis (MS) were treated by an induction Cyclophosphamide (CFX) schedule followed by bimonthly boosters over one year. Of the 14 patients who completed the trial, only two displayed worsening of neurological status. Cerebrospinal fluid (CSF) total protein, IgG/Alb ratio and IgG index decreased at 6 months and were still low at the end of the treatment. Pretreatment percentages of PB CD8+ and CD4+CD45RA+ lymphocytes were lower in MS patients in comparison with healthy controls. However, no significant shifts occurred in percentage of PB CD4+, CD4+CD45RA+, CD4+CD45RA-, CD8+ lymphocytes of MS patients during immunosuppressive treatment. The lack of changes in the investigated immunological parameters contrasts with the good clinical response and the low rate of serious side effects during this treatment schedule.

KW - Cerebrospinal fluid

KW - Cyclophosphamide

KW - Multiple Sclerosis

KW - T-cell subsets

UR - http://www.scopus.com/inward/record.url?scp=0028449195&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028449195&partnerID=8YFLogxK

U2 - 10.3109/00207459408986012

DO - 10.3109/00207459408986012

M3 - Article

VL - 76

SP - 305

EP - 312

JO - International Journal of Neuroscience

JF - International Journal of Neuroscience

SN - 0020-7454

IS - 3-4

ER -